Durham, NCNCT05546580Now EnrollingIRB Ready

Acute Myeloid Leukemia, in Relapse Clinical Trial in Durham, NC

Access cutting-edge acute myeloid leukemia, in relapse treatment through this clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by Oryzon Genomics S.A.

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access acute myeloid leukemia, in relapse specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia, in relapse treatment provided free

Apply for This Durham Location

Check if you qualify for this acute myeloid leukemia, in relapse clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia, in Relapse Study in Durham

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.

Sponsor: Oryzon Genomics S.A.

Who Can Participate

Inclusion Criteria

Diagnosis of primary AML or AML with myelodysplasia-related changes (AML-MRC)
Patient is in first or second relapse or has refractory disease. Patients must have had histologic verification of AML at the original diagnosis.
Patient must be positive for the following FLT3 mutations in bone marrow or PB: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD) D835 or I836 or FLT3-ITD and specified FLT3-TKD.
ECOG performance status 0-2
Life expectancy of at least 3 months in the opinion of the investigator.
Normal hepatic and renal function.
Patient is able to swallow oral medications.
Female patients are postmenopausal, documented as surgically sterile, use two methods of contraception or practice true abstinence and have a negative urine pregnancy test at screening.
Male patients even if surgically sterilized agree to practice true abstinence or use highly effective barrier contraception. Main

Exclusion Criteria

Diagnosis of acute promyelocytic leukemia.
Known BCR-ABL-positive leukemia.
AML secondary to prior chemotherapy for other neoplasms (except for MDS).
AML that has relapsed after or is refractory to more than 2 lines of therapy.
Clinically active central nervous system leukemia or prior history of NCI CTCAE Grade ≥ 3 drug-related CNS toxicity.
Major surgery or radiation therapy within 4 weeks prior to the first study dose.
Prior treatment with iadademstat is not allowed. Treatment with any other agents with KDM1A/LSD1 inhibitory activity is only allowed if treatment finalized at least 3 weeks prior to first dose on study. Previous treatment with FLT3 inhibitors is allowed in the following cases: midostaurin and sorafenib are allowed when used in first-line therapy regimen as part of induction, consolidation and/or maintenance: quizartinib and gilteritinib are allowed when used in first-line therapy regimen, as part of induction, consolidation and/or maintenance, ONLY if patients were not refractory to the drugs or if responding, relapse did not occur while on these drugs.
Patients not eligible to receive gilteritinib per label.
Prior treatment with 3 or more lines of AML therapy.
Treatment with any investigational products within 3 weeks prior to first dose of study treatment.
Uncontrolled hypertension or poorly controlled diabetes.
Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
Pregnant or lactating women.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT05546580) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia, in Relapse Treatment Options in Durham, NC

If you're searching for acute myeloid leukemia, in relapse treatment options in Durham, NC, this clinical trial (NCT05546580) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia, in relapse specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia, in relapse clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Durham, NC

See all leukemia clinical trials recruiting in Durham — not just this study.

Browse Leukemia Trials in Durham →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsAntiphospholipid Syndrome TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC